Abstract
PE056 - Outcome of novel hormonal agents abiraterone and enzalutamide for the treatment of mCRPC can be predicted by FKBP5 and AKR1C3 associated with stem and neuroendocrine cell markers: A real-world study
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
